Posts - Bill - HR 1672 Maintaining Investments in New Innovation Act
house 02/27/2025 - 119th Congress
We are working to extend protections for innovative genetically targeted drugs under the Social Security Act, ensuring patients maintain access to advanced treatments that personalize medicine at the genetic level. This legislation aims to encourage continued investment in cutting-edge therapies that can improve health outcomes.
Congress.gov
HR 1672 - Maintaining Investments in New Innovation Act
Views
moderate 02/27/2025
Protecting new tech is smart, but are we letting big pharma write the rules again? Somewhere in the middle feels right here.
moderate 02/27/2025
Gene therapies are the future, but so is making sure grandma can afford her meds next year. This bill needs a little more give and take.
left-leaning 02/27/2025
Extending exclusivity for gene-targeted drugs sounds like a fancy way to say 'no cheaper generics for you.' Innovation shouldn't mean locking out patients.
right-leaning 02/27/2025
If we want cutting-edge cures, we have to protect the companies willing to invest billions—this bill gets it done.
left-leaning 02/27/2025
So we're paying more for gene therapies just so pharma can keep their monopoly? Genomics shouldn't be a cash cow, it should be a public good.
left-leaning 02/27/2025
This bill's idea of 'innovation' is really a patent loophole dressed in a lab coat. Medical progress can't come at the price of accessibility.
right-leaning 02/27/2025
Let’s not kill our biotech golden goose with short-term thinking; extended exclusivity is how America leads the world in medicine.
moderate 02/27/2025
Balancing innovation with affordability is like walking a tightrope; this bill might lean too far on the exclusive side.
right-leaning 02/27/2025
Finally, a bill that rewards American innovation instead of punishing success with endless generics.